Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Aug;20(4):e283-8.
doi: 10.3747/co.20.1380.

Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer

F Morgillo  1 , F De Vita, G Antoniol, M Orditura, P P Auriemma, M R Diadema, E Lieto, B Savastano, L Festino, M M Laterza, A Fabozzi, J Ventriglia, A Petrillo, F Ciardiello, A Barbarisi, F Iovino
Affiliations

Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer

F Morgillo et al. Curr Oncol. 2013 Aug.

Abstract

Increased insulin-like growth factor (igf) signalling has been observed in breast cancer, including endocrine-responsive cancers, and has been linked to disease progression and recurrence. In particular, igf-1 has the ability to induce and promote lymphangiogenesis through the induction of vascular endothelial growth factor C (vegfc). In the present study, we analyzed serum and tumour samples from 60 patients with endocrine-positive breast cancer to determine the expression and the possible relationship of circulating igf-1, igf binding protein 3 (igfbp3), and vegfc with the presence of lymphatic metastasis and other immunohistochemical parameters. The analysis revealed a clear and significant correlation between high basal levels of igf-1, igfbp3, and vegfc and lymph node metastasis in endocrine-responsive breast cancer. In addition, expression of those molecules was significantly higher in breast cancer patients than in healthy control subjects. Those findings may enable more accurate prediction of prognosis in patients with breast cancer.

Keywords: Breast cancer; igf-1; vegfc.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Levels of insulin-like growth factor 1 (igf-i), igf binding protein 3 (igfbp3), and vascular endothelial growth factor C (vegfc) in healthy control subjects and in breast cancer patients.
See this image and copyright information in PMC

References

    1. Yee D. The insulin-like growth factors and breast cancer—revisited. Breast Cancer Res Treat. 1998;47:197–9. doi: 10.1023/A:1005938615798. - DOI - PubMed
    1. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 2000;92:1472–89. doi: 10.1093/jnci/92.18.1472. - DOI - PubMed
    1. Wilker E, Lu J, Rho O, Carbajal S, Beltrán L, DiGiovanni J. Role of pi3k/Akt signaling in insulin-like growth factor-1 (igf-1) skin tumor promotion. Mol Carcinog. 2005;44:137–45. doi: 10.1002/mc.20132. - DOI - PubMed
    1. Yakar S, Leroith D, Brodt P. The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: lessons from animal models. Cytokine Growth Factor Rev. 2005;16:407–20. doi: 10.1016/j.cytogfr.2005.01.010. - DOI - PubMed
    1. Sachdev D, Yee D. Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer. J Mammary Gland Biol Neoplasia. 2006;11:27–39. doi: 10.1007/s10911-006-9010-8. - DOI - PubMed

LinkOut - more resources